TRAW — Traws Pharma, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-06-01.
Performance
Technicals
Others in Healthcare
Measured signals that fired on TRAW
| date | signal | measured base rate |
|---|---|---|
| 2026-05-15 | Institutional holders jumped in a quarter ownership | -0.52% over 21 days · t = -0.38 · n = 1,553 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-04-16 | ORBIMED ADVISORS LLC 10% owner | Open-market purchase | 597.7K | 1.67 | 998.2K |
| 2026-04-16 | OrbiMed Capital GP VIII LLC 10% owner | Open-market purchase | 597.7K | 1.67 | 998.2K |
| 2025-12-12 | Clarke Trafford Director | Grant or award | 6.2K | 0.00 | 0 |
| 2025-12-12 | Shoemaker Mary Teresa Director | Grant or award | 6.2K | 0.00 | 0 |
| 2025-12-12 | Leaman John Harold Director | Grant or award | 4.1K | 0.00 | 0 |
| 2025-12-12 | Redfield Robert Chief Medical Officer | Grant or award | 16.4K | 0.00 | 0 |
| 2025-12-12 | CAUTREELS WERNER Director | Grant or award | 4.9K | 0.00 | 0 |
| 2025-12-12 | Pauza Charles David Chief Science Officer Virology | Grant or award | 18.5K | 0.00 | 0 |
| 2025-12-12 | Savchuk Nikolay Chief Operating Officer | Grant or award | 16.4K | 0.00 | 0 |
| 2025-12-12 | Parker Charles Nolan Chief Financial Officer | Grant or award | 15.4K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.3M | 730.0K |
| Ikarian Capital, LLC | 1.2M | 678.1K |
| ORBIMED ADVISORS LLC | 1.1M | 605.5K |
| Squadron Capital Management LLC | 936.4K | 511.7K |
| Dauntless Investment Group, LLC | 763.1K | 417.0K |
| BOOTHBAY FUND MANAGEMENT, LLC | 356.0K | 194.5K |
| ADAR1 Capital Management, LLC | 282.0K | 154.1K |
| GEODE CAPITAL MANAGEMENT, LLC | 141.1K | 77.1K |
| Palumbo Wealth Management LLC | 112.0K | 61.2K |
| VANGUARD CAPITAL MANAGEMENT LLC | 101.0K | 55.2K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-12 | — | on EDGAR ↗ |
| 8-K | 2026-07-31 | 2026-07-29 | on EDGAR ↗ |
| 4 | 2026-07-16 | 2026-07-09 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Traws Pharma GAAP EPS of -$0.16 beats by $0.06 · 2026-08-17
- Traws Pharma, Inc. (TRAW) filed form 8-K · 2026-08-14 · SEC EDGAR
- Traws Pharma, Inc. (TRAW) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
- Traws Pharma, Inc. (TRAW) filed form 10-Q · 2026-08-14 · SEC EDGAR
- Traws Pharma, Inc. (TRAW) filed form 8-K · 2026-08-14 · SEC EDGAR
- Traws Pharma, Inc. (TRAW) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
Ask the AI about TRAW
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →